Obermatt

Oramed Pharmaceuticals

NAQ:ORMP · US68403P2039
PharmaceuticalsSmall

360

47
Profit price37
Owner Earnings Yield100
Dividend Yield1
Price/Sales1
Price/Book92
Return on Capital44
Cash Return on Capital100
Return on Equity98
Profit margins6
Cash Conversion7
Accruals1
Sales growth1
Profit growth95
Reinvestment37
Price momentum80
Debt load93
Refinancing20
Debt Payback100
Liquidity12
Analyst ratings
Opinion Changes50
Price Target Upside38
Market mood1
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Oramed Pharmaceuticals clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2002
Employees9
Websiteoramed.com
ISINUS68403P2039
Last UpdateApr 2, 2026
Themes
DiabetesInfectious DiseasesEndocrinologyVaccinesHealth CareMedicalPharmaceutical

Description

Oramed Pharmaceuticals Inc. (Oramed), a pharmaceutical company, engages in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an or…

Analysis

Middle-of-the-road

Oramed Pharmaceuticals Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is attractive. You pay 1.4× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is moderate and the balance sheet is adequate. The company scores 12/20 on our value-creation score: creating some value. Analysts lean positive.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
40
2026

All-time high

40

Jun 2026

All-time low

23

Mar 2026

Average rank

32

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
1
Price/Earnings
100
Price/Book
92
Dividend Yield
1
Value (overall)
96

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Oramed Pharmaceuticals with its peers
Terns Pharmaceuticals
NSQ:TERN
96
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
MBX Biosciences
NSQ:MBX
30
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Ventyx Biosciences
NSQ:VTYX
51
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Phathom Pharmaceuticals
NSQ:PHAT
37
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Relmada Therapeutics
NAQ:RLMD
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Structure Therapeutics
NMQ:GPCR
67
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →